ReviewExperimental & molecular medicine2021
Slimy partners: the mucus barrier and gut microbiome in ulcerative colitis.
Review in Experimental & molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Sodium Butyrate Therapy in Ulcerative Colitis: A Systematic Review of Preclinical and Clinical Evidence.Medical sciences (Basel, Switzerland) · 2026Pooled it
- Research trends of intestinal barrier in ulcerative colitis: a bibliometric analysis.Frontiers in medicine · 2025Pooled it
- Prebiotics for induction and maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2024Pooled it
- Trial
- Biohybrid magnetic carrier robots for targeted bacteria release in ulcerative colitis.Materials today. Bio · 2026Article
- Integrated Multi-Omics Reveals Complementary Luminal and Mucosal Host-Microbiome Interactions Associated with Disease Activity and Phenotype in Paediatric Inflammatory Bowel Disease.Microorganisms · 2026Article
- Unique adaptations in sulfatases underpin colonic mucin degradation by Akkermansia muciniphila.Nature microbiology · 2026Article
- Antisense transcription reveals disease-associated adaptations in the human gut microbiome.Nature microbiology · 2026Article
- A c-di-AMP receptor mediates epithelial adhesion of Lactiplantibacillus plantarum.Nature communications · 2026Article
- Food-Derived Biohybrid Probiotic Extracellular Vesicles for Synergistic Therapy of Inflammatory Bowel Disease.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Gastrointestinal Tract Remodeling by Dietary Polysaccharides Mechanistic Insights in Colitis-A Review.Foods (Basel, Switzerland) · 2026Review
- Novel Perspectives on the Relationship Between the Gastrointestinal Mucus Barrier and Soybean Agglutinin.Cells · 2026Review
- Jabuticaba (Nutrients · 2026Article
- TIGAR regulates intestinal mucus barrier integrity by inhibiting lactylation of G6PD/6PGD in ulcerative colitis.Nature communications · 2026Article
- HMGB1 functions as a critical mediator of host defense at the gut mucosal barrier.Cell host & microbe · 2026Article
- Flos sophorae immaturus exosome-like nanovesicles alleviate ulcerative colitis by attenuating intestinal oxidative stress and inflammation through activating Aryl hydrocarbon receptor via gut microbiota and tryptophan metabolism regulation.Journal of nanobiotechnology · 2026Article
- Managing Acute Severe Ulcerative Colitis in 2025 and Beyond.Current gastroenterology reports · 2026Review
- Beyond bacterial dysbiosis: the emerging role of gut bacteriophages in type 2 diabetes.Frontiers in cell and developmental biology · 2026Review
- Microbiota-miR-101 interactions in obesity-associated colorectal cancer: from barrier dysfunction to precision therapeutic strategies.Frontiers in pharmacology · 2026Review
- The Intricate Interplay of Noncoding RNAs and the Gut Microbiome in Gastrointestinal and Endocrine-Related Cancers.Sub-cellular biochemistry · 2026Review
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic recurrent intestinal inflammatory disease characterized by high incidence and young onset age. Recently, there have been some interesting findings in the pathogenesis of UC. The mucus barrier, which is composed of a mucin complex rich in O-glycosylation, not only provides nutrients and habitat for intestinal microbes but also orchestrates the taming of germs. In turn, the gut microbiota modulates the production and secretion of mucins and stratification of the mucus layers. Active bidirectional communication between the microbiota and its 'slimy' partner, the mucus barrier, seems to be a continually performed concerto, maintaining homeostasis of the gut ecological microenvironment. Any abnormalities may induce a disorder in the gut community, thereby causing inflammatory damage. Our review mainly focuses on the complicated communication between the mucus barrier and gut microbiome to explore a promising new avenue for UC therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.